These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17895469)

  • 1. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 2. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic adenocarcinoma.
    Ryan DP; Hong TS; Bardeesy N
    N Engl J Med; 2014 Sep; 371(11):1039-49. PubMed ID: 25207767
    [No Abstract]   [Full Text] [Related]  

  • 4. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 5. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 6. Autophagy, p53, and pancreatic cancer.
    Iacobuzio-Donahue CA; Herman JM
    N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
    [No Abstract]   [Full Text] [Related]  

  • 7. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine.
    Roukos DH
    Expert Rev Mol Diagn; 2009 Apr; 9(3):217-21. PubMed ID: 19379079
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 9. The littlest patient.
    Couzin-Frankel J
    Science; 2014 Oct; 346(6205):24-7. PubMed ID: 25278593
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 11. Targets, trials, and travails in pancreas cancer.
    Izeradjene K; Hingorani SR
    J Natl Compr Canc Netw; 2007 Nov; 5(10):1042-53. PubMed ID: 18053428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 14. Shining the spotlight on shed KRAS in pancreatic cancer.
    Sempere LF; Korc M
    Cancer Biol Ther; 2008 Mar; 7(3):361-3. PubMed ID: 18614859
    [No Abstract]   [Full Text] [Related]  

  • 15. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 16. Applying synthetic lethality for the selective targeting of cancer.
    McLornan DP; List A; Mufti GJ
    N Engl J Med; 2014 Oct; 371(18):1725-35. PubMed ID: 25354106
    [No Abstract]   [Full Text] [Related]  

  • 17. An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity.
    Ruppen-Cañás I; López-Casas PP; García F; Ximénez-Embún P; Muñoz M; Morelli MP; Real FX; Serna A; Hidalgo M; Ashman K
    Proteomics; 2012 May; 12(9):1319-27. PubMed ID: 22589181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy of pancreatic cancer.
    Chaulagain CP; Ng J; Wazer D; Saif MW
    JOP; 2012 Jul; 13(4):349-53. PubMed ID: 22797387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly methylated genes in colorectal neoplasia: implications for screening.
    Zou H; Harrington JJ; Shire AM; Rego RL; Wang L; Campbell ME; Oberg AL; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2686-96. PubMed ID: 18086775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rat virus visits the clinic: translating basic discoveries into clinical medicine in the 21st century.
    Boland CR; Goel A
    Gut; 2003 Jan; 52(1):8-9. PubMed ID: 12477748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.